The Oncomine™ Immune Response Research Assay is a targeted, next-generation sequencing (NGS) gene expression assay that enables immuno-oncology research through the quantitative evaluation of the expression of markers associated with different leukocyte subsets, antigen presentation, checkpoint pathways, and tumor progression. The assay measures the expression of genes involved in tumor-immune interactions, including the low-expressing genes involved in inflammatory signaling.
Designed with comprehensive coverage of targets associated with key genes relevant to immune response biomarker research, the Oncomine Immune Response Research Assay achieves superior performance in the detection of low-expressing genes from as little as 10 ng input RNA from FFPE research samples.
The assay offers:
Figure 1. The Oncomine Immune Response Research Assay is intended for biomarker profiling applications. Signatures you detect with the assay may lead to separate clinical trial assay and companion diagnostic development efforts in the future.
The Oncomine Immune Response Research Assay features content designed for future clinical trial research cohorts.
Functional annotation group
Number of genes
Functional annotation group
Number of genes
B cell marker
Innate immune response
Dendritic cell, macrophage
Helper T cells
B cell receptor signaling
NK cell marker
T cell receptor signaling
T cell differentiation
T cell regulation
Type I interferon signaling
Type II interferon signaling
Table 1. Oncomine Immune Response Research Assay content includes 395 genes across 36 functional annotation groups comprised of genes associated with lymphocyte regulation, cytokine signaling, lymphocyte markers, checkpoint pathways, and tumor characterization.
The Oncomine Immune Response Research Assay contains key clinical cancer research targets including cytokine signaling genes like IFNG, drug target genes like CTLA4, and PD-1 signaling genes like MTOR and PTEN.
Figure 2. Range of expression across 10 pancancer research samples. The Oncomine Immune Response Research Assay demonstrates improved detection over the competitor N assay when interrogating key immune response research gene subsets including low-expression genes associated with both T cell receptor signaling and checkpoint pathways.
Current PD-1 and PD-L1 assays may miss important genes that can indicate immune response. Further, throughput and reproducibility challenges with IHC make it difficult to conduct robust studies. The Oncomine Immune Response Research Assay addresses these challenges.
Part of a comprehensive solution including automation with the Ion Chef System and Ion S5 System, the assay contains the reagents for library construction and a single pool of primers used to perform multiplex PCR for preparation of amplicon libraries from formalin-fixed paraffin-embedded (FFPE) samples. Achieving 4, 8, or 32 samples per run depending on your throughput needs, the workflow gives you the flexibility to run small or large retrospective or prospective profiling research studies.
Figure 3. Current immunotherapy research with IHC lacks reproducibility and does not scale beyond 1–2 assays per tumor sample (left). The Oncomine Immune Response Research Assay can provide insights about the composition of the tumor microenvironment that may improve stratification of samples (right).
Figure 4. Preliminary indicator that may aid in improved stratification of samples. The Oncomine Immune Response Research Assay achieves better stratification of samples compared to the competitor N assay evident in the clearer distinction between cancer types when clustered by all genes shared by each panel.
Supported on Ion S5 and Ion PGM™ Sequencers, the Oncomine Immune Response Research Assay enables your lab to efficiently run small- and large-scale studies.
The optimized informatics and visualization software minimizes the complexity of data analysis. The analysis workflow consists of a data exploration component automated by the Immune Response Torrent Suite™ Plug-in, and a two-group differential analysis provided by the Affymetrix™ Transcriptome Analysis Console (TAC). Together these tools offer a streamlined process for common gene expression analyses and exportable data files that are amenable to further exploration with other third-party software.
These tools enable:
Figure 5. The Oncomine Immune Response Research Assay includes reagents for library construction, primers for library preparation, and analysis software for interpretation of results. *Two-day workflow requires overnight template preparation.
For Research Use Only. Not for use in diagnostic procedures.